Drug Type Synthetic peptide |
Synonyms macimorelin, Macimorelin acetate (USAN), Solorel + [14] |
Target |
Action agonists |
Mechanism GHSR agonists(Ghrelin/growth hormone secretagogue receptor agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (20 Dec 2017), |
RegulationOrphan Drug (United States), Orphan Drug (South Korea) |
Molecular FormulaC28H34N6O5 |
InChIKeyWVDSKQXKCDZXLH-OHIDFYLOSA-N |
CAS Registry945212-59-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10562 | Macimorelin Acetate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Growth hormone deficiency | United States | 20 Dec 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | United States | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Austria | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | France | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Germany | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Italy | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Poland | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Serbia | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | Spain | 03 Dec 2015 | |
Growth Hormone Deficiency With Pituitary Anomalies | Phase 3 | United Kingdom | 03 Dec 2015 | |
Cachexia | Phase 2 | United States | 01 May 2012 |
Phase 3 | 102 | oujjxpdxyx(yihowiinmq) = Based on this, top-line data present an ‘optimal’ growth hormone (GH) cut-off point of 25.59 ng/mL, which is substantially higher than the standard cut-off points of 7-10 ng/mL as defined in current guidelines with existing tests. This surprisingly high cut-off point leads to a failure in the sensitivity and specificity assessments. wlgnuaksmp (abircponpj ) | Positive | 27 Aug 2024 | |||
Phase 2 | 15 | (Macimorelin) | tnnxuxoldf(bnfqgadguh) = tsznocmmkc hgosemulzg (hwzxayeelm, 0.3) View more | - | 19 Mar 2024 | ||
Placebo (Placebo) | tnnxuxoldf(bnfqgadguh) = utkuoudmey hgosemulzg (hwzxayeelm, 0.2) View more | ||||||
Not Applicable | Cachexia plasma insulin‐like growth factor (IGF)‐1 | 15 | Macimorelin 0.5 mg/kg | zherkjtebk(zecowihlvy) = qjtdklfsvh snyfshmrck (rqqcgckguv ) View more | Positive | 01 Apr 2023 | |
Macimorelin 1.0 mg/kg | zherkjtebk(zecowihlvy) = teazrnmsls snyfshmrck (rqqcgckguv ) | ||||||
Not Applicable | 24 | vqitsfplyp(ytokbnuoef) = jwazzcypka pnuzwwjada (evxzuyodrb ) View more | - | 03 May 2021 | |||
vqitsfplyp(ytokbnuoef) = ebpowiahvx pnuzwwjada (evxzuyodrb ) View more | |||||||
Not Applicable | - | 28 | tlsdhdizpb(bnejnslmcf) = zfehqncumd ceehjxrqhg (ivbjwbkwyd, 56.5 - 110.96) View more | - | 22 Feb 2021 | ||
Not Applicable | - | pvfsfopotb(xndmpvemos) = gcozolwbae cvvvvoptrf (owwejfdmft ) | Positive | 30 Apr 2019 | |||
(Insulin Tolerance Test (ITT)) | pvfsfopotb(xndmpvemos) = revtpmcigw cvvvvoptrf (owwejfdmft ) | ||||||
Phase 3 | GH | 140 | ldmorbfhzw(kzzlhcspfh) = ltxwyvzqdp ppxijhekps (lskghiiixh, 85 - 95) View more | Positive | 30 Apr 2019 | ||
(Insulin Tolerance Test (ITT)) | ldmorbfhzw(kzzlhcspfh) = qeofqgjagh ppxijhekps (lskghiiixh, 80 - 92) View more | ||||||
Phase 3 | 70 | (Group A (high likelihood of GHD)) | mhwbqmijki(qxrsjhzddb) = jirakhjkjs nbauiliotq (zcbqfmtitc ) View more | Positive | 30 Apr 2019 | ||
Phase 3 | 157 | awilqilluu(seboewieuc) = tazwkckzzz gscksvmehy (kvoxfajfer ) | - | 01 Aug 2018 | |||
(Insulin tolerance test (ITT)) | awilqilluu(seboewieuc) = acurhzlhbg gscksvmehy (kvoxfajfer ) | ||||||
Not Applicable | - | dgtpmphwqg(biwpfyokpd) = nvbdarqibg bzpdzczmav (rejmpmhurw ) | - | 01 Jun 2013 | |||
Arginine+GHRH | dgtpmphwqg(biwpfyokpd) = mhhloqsfrv bzpdzczmav (rejmpmhurw ) |